OS Therapies announced favorable FDA feedback on external control arm strategy for OST-HER2 in pediatric osteosarcoma. Read more on this news via Drug Discovery & Development: bit.ly/3Gof9JE $OSTX #PediatricOncology #Osteosarcoma

OST-HER2 and the Fight Against Osteosarcoma - A New Hope After 40 Years. Join CEO Paul Romness discussing breakthrough targeted therapies for #osteosarcoma, a rare bone cancer affecting humans and dogs. Tune in: bit.ly/3G5pJW5 $OSTX #PrecisionMedicine

OST-HER2 shows positive 1 year EFS improvement in the prevention or delay of recurrence in fully resected, pulmonary metastatic #osteosarcoma. A new article via CancerNetwork® highlights our recent data updates. Read more here: bit.ly/45NjLDD $OSTX

OS Therapies announced it was granted an End of Phase 2 meeting by US FDA for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic #osteosarcoma. Read the press release: bit.ly/4lF8JVK $OSTX #Oncology #Biopharma

ICYMI: OST-HER2 achieved 35% 1-year event free survival vs 20% historical control in fully resected, lung metastatic #osteosarcoma patients. "The favorable safety profile of OST-HER2 compared with standard of care is also an important quality of life factor" - Dr. Robert Petit,

OST-HER2 achieves statistically significant positive 1-year EFS in pulmonary metastatic #osteosarcoma. Read more via Drug Discovery World: bit.ly/4nyU7Jj $OSTX #RareDisease #PediatricCancer #Biotech #ClinicalTrials

Today, OS Therapies provided a clinical and global regulatory update on its currently active clinical-stage #oncology programs. The End of Phase 2 Meeting granted by the US FDA to review the clinical data from its OST-HER2 recurrent, pulmonary metastatic osteosarcoma program is

Huge congrats! 🎉 "Shelter Me: The Cancer Pioneers," featuring OS Therapies' OST-HER2, earned 2 Daytime Emmy nominations! 🏆 This film showcases the drive for new cancer treatments. Support for the film champions vital medical innovation as we advance toward BLA for OST-HER2

Today, OS Therapies announced that it has closed its $4.2M warrant exercise inducement and exchange offer, extending its runway through 2026. The company intends to use the net proceeds primarily to support U.S. and international regulatory and pre-commercial efforts aimed at

OS Therapies remains focused on our regulatory plan: End of Phase 2 Meeting with the FDA in the United States and our Scientific Advice Meetings in the United Kingdom and Europe. This delivers on our core mission of improving the treatment landscape for metastatic osteosarcoma

New article in Precision Medicine Online highlights how our recent funding will support U.S. and international regulatory and pre-commercial efforts aimed at securing accelerated marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary

In an exclusive interview with The Fly, $OSTX CEO Paul Romness discusses becoming a "commercial #biotech company by early 2026" with OST-HER2 immunotherapy for #osteosarcoma and the potential $160M+ priority review voucher. Read: bit.ly/46ndxL3 #RareDisease

Global unity in the face of uncertainty, with $OSTX CEO Paul Romness & EVERSANA VP of Business Development Farah Ahmad. Tune in to an impressive discussion during #BIO2025 about our relationship with EVERSANA as we advance clinical-stage programs: bit.ly/4kR4sNQ

OS Therapies CEO Paul Romness on the #NYSE floor with Jon Najarian. Stay tuned! $OSTX

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic #Osteosarcoma. Read the press release:

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma. Read more in the press release:

OS Therapies' regulatory activities for novel immunotherapy, OST-HER2, are progressing. The company received positive feedback from UK MHRA Scientific Advice Meeting and submitted ILAP application for OST-HER2. MHRA suggested Project Orbis to align UK and US approval processes.

OS Therapies advances regulatory pathway for bone cancer therapy pharmafile.com/news/os-therap…

OST-HER2 yields statistically significant positive interim 2-year overall survival data from phase 2b #clinicaltrial in the prevention or delay of recurrent, fully resected, pulmonary metastatic #osteosarcoma. Read more via CancerNetwork®: bit.ly/3JbI1G6 $OSTX

OS Therapies advances regulatory pathway for OST-HER2, its immunotherapy for osteosarcoma. MHRA Scientific Advice Meeting completed EMA Scientific Advice Meeting scheduled October 2025 FDA BLA submission planned for 2025 Read: bit.ly/3Jbrh1M $OSTX #Oncology